Literature DB >> 20856243

Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics.

L G Osterberg1, J Urquhart, T F Blaschke.   

Abstract

The usual objective during long-term pharmacotherapy is, in large part, to maintain continuity of action of the prescribed drug(s). Continuity of action arises from the continuity of execution of a prescribed dosing regimen that is pharmacologically sound in dose quantity and interval between successive doses. Interruptions in dosing can interrupt drug action, but the consequences vary according to length of interruption, drug, drug formulation, length of the patient's prior exposure to the drug, and the disease being treated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20856243     DOI: 10.1038/clpt.2010.171

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

Review 1.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

2.  Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).

Authors:  Bernard Vrijens; Marc J Claeys; Victor Legrand; Eef Vandendriessche; Frans Van de Werf
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

3.  The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients.

Authors:  Peter W de Leeuw; Robert Fagard; Abraham A Kroon
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

4.  What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.

Authors:  Tao Xiao; Zhanzhang Wang; Guanlie Li; Shanqing Huang; Xiuqing Zhu; Shujing Liu; Xiaolin Li; Jinqing Hu; Dewei Shang; Yuguan Wen
Journal:  Drug Des Devel Ther       Date:  2021-08-04       Impact factor: 4.162

5.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

Review 6.  Effects of Antihypertensive Therapy on Blood Pressure Variability.

Authors:  Kazuo Eguchi
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

7.  Discordance Between Drug Adherence as Reported by Patients and Drug Importance as Assessed by Physicians.

Authors:  Stéphanie Sidorkiewicz; Viet-Thi Tran; Cécile Cousyn; Elodie Perrodeau; Philippe Ravaud
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

8.  Validation of a New Three-Item Self-Report Measure for Medication Adherence.

Authors:  Ira B Wilson; Yoojin Lee; Joanne Michaud; Floyd J Fowler; William H Rogers
Journal:  AIDS Behav       Date:  2016-11

9.  The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Ian M Kronish; Amy I Lynch; Suzanne Oparil; Jeff Whittle; Barry R Davis; Lara M Simpson; Marie Krousel-Wood; William C Cushman; Tara I Chang; Paul Muntner
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

Review 10.  Renal denervation: ultima ratio or standard in treatment-resistant hypertension.

Authors:  Alexandre Persu; Jean Renkin; Lutgarde Thijs; Jan A Staessen
Journal:  Hypertension       Date:  2012-07-30       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.